News & Blog

News & Blog

  • Reset
News | Oct 16 2024

Papillon Therapeutics Receives Rare Pediatric Disease Designation from the U.S. Food and Drug Administration for PPL-001 for the Treatment of Friedreich’s Ataxia

Industry News
News | Oct 8 2024

PTC Therapeutics Announces Positive Results from Long-Term Treatment Studies and Updates on Regulatory Progress for Vatiquinone Friedreich Ataxia Program

Industry News
News | Sep 20 2024

Congressional Resolution Passes to Designate September 25 as “National Ataxia Awareness Day”

Advocacy
News | Sep 17 2024

Papillon Therapeutics Receives Orphan Drug Designation from the U.S. Food and Drug Administration for PPL-001 for the Treatment of Friedreich’s Ataxia

Industry News
News | Sep 11 2024

Stealth BioTherapeutics Awarded Grant from Friedreich’s Ataxia Research Alliance and FARA Ireland to Develop Investigational Mitochondrial Therapeutic SBT-589 for Friedreich’s Ataxia

FARA News | Industry News | Research
News | Sep 10 2024

Meet the 2024 FARA Fellows

FARA News | Research
News | Sep 4 2024

FA Community Conversations Genetic Therapies Webinar: Recording Available on YouTube

Education
News | Aug 27 2024

FARA Celebrates 16 Years of Funding Adaptive Cycling Equipment Through The Ataxian Athlete Initiative (AAI) 

rideATAXIA
News | Aug 22 2024

United Against Ataxia Hill Day 2024 – Registration open!

Advocacy | FARA News
News | Aug 19 2024

August 2024 – Advocacy Newsletter

Advocacy
News | Aug 14 2024

Join us for FA Community Conversations – Genetic Medicine on August 29, 2024

Education
News | Aug 7 2024

Larimar Therapeutics Reports Several Updates on Nomlabofusp FA Program in Q2 2024 Operating and Financial Results

Industry News